drugset / Trial / NCT00675649

A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma

NCT00675649

Phase 2 Withdrawn Centocor, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety and effects (good and bad) of golimumab therapy in patients with severe, persistent asthma.

Timeline

Start
2008-05
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Golimumab Monoclonal antibody 100 mg Subcutaneous

Indications